Comments on: U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Comments on: U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis https://www.novumpr.nl/2019/05/09/u-s-food-drug-administration-accepts-takedas-biologics-license-application-for-a-subcutaneous-formulation-of-vedolizumab-entyvio-for-maintenance-therapy-in-moderately-to-severe/?utm_source=rss&utm_medium=rss&utm_campaign=u-s-food-drug-administration-accepts-takedas-biologics-license-application-for-a-subcutaneous-formulation-of-vedolizumab-entyvio-for-maintenance-therapy-in-moderately-to-severe NovumPR press releases Thu, 09 May 2019 11:43:11 +0000 hourly 1 https://wordpress.org/?v=6.8.3